American Academy of Dermatology (AAD), 2024

Bimekizumab efficacy and safety through 4 years in moderate to severe plaque psoriasis: Long-term results from the BE SURE trial and BE BRIGHT open-label extension

Bimekizumab efficacy in moderate to severe plaque psoriasis: Improvements in symptom severity assessed using Psoriasis Symptoms and Impacts Measure (P-SIM) thresholds in BE VIVID and BE SURE

Bimekizumab safety and tolerability in moderate to severe plaque psoriasis: Pooled analysis from up to 4 years of treatment in 5 phase 3/3b clinical trials

Normalization of molecular signatures associated with pruritis in plaque psoriasis correlate with itch resolution following bimekizumab treatment

Bimekizumab improvement in three Dermatology Life Quality Index (DLQI) items capturing aspects most burdensome to patients with moderate to severe plaque psoriasis

Bimekizumab efficacy and safety in Japanese patients with generalized pustular psoriasis and erythrodermic psoriasis: 3 year results from BE BRIGHT, a multicenter, open label, phase 3 study

Bimekizumab 4-year maintenance of responses in Week 16 responders with moderate to severe plaque psoriasis: Results from the BE BRIGHT open-label extension phase 3 trial

Bimekizumab efficacy across subgroups of patients with moderate to severe plaque psoriasis: Pooled analysis from up to 3 years of treatment in 5 phase 3/3b clinical trials

Bimekizumab treatment resulted in rapid and sustained improvement in total and individual Bath Ankylosing Spondylitis Disease Activity Index components in patients with psoriatic arthritis: 1-year results from two phase 3 studies

Bimekizumab treatment resulted in sustained improvements in nail psoriasis and signs and symptoms of psoriatic arthritis in patients with baseline nail disease: 1-year pooled results from two phase 3 studies

Bimekizumab treatment resulted in sustained improvements in pain and fatigue in patients with active psoriatic arthritis and baseline psoriasis: 1-year results from two phase 3 studies

Bimekizumab and secukinumab comparative effectiveness in hidradenitis suppurativa: Indirect treatment comparisons at Week 16 and 1 Year

Bimekizumab impact on draining tunnels in patients with moderate to severe hidradenitis suppurativa: Pooled 48-week data from BE HEARD I & II

Bimekizumab impact on concomitant rescue interventions in patients with moderate to severe hidradenitis suppurativa in BE HEARD I & II